Trustees of the Welfare and Pension Funds of Local 464A, The v. Medtronic plc

Background

Lead plaintiffs Phoenix Insurance Company Ltd. and Phoenix Provident Pension Fund Ltd. (collectively 'Phoenix') brought this putative securities class action on behalf of investors who purchased Medtronic PLC common stock between May 23, 2019, and May 26, 2022. The defendants are Medtronic PLC and four of its executives: Geoffrey S. Martha (President and later CEO), Karen L. Parkhill (Executive Vice President and Chief Financial Officer), Sean Salmon (President of the Diabetes Group beginning October 2019), and Hooman Hakami (President of the Diabetes Group until October 2019).

Medtronic's Diabetes Group manufactures the MiniMed line of insulin pumps, which are medical devices that deliver insulin to patients with diabetes. Manufacturing defects in a component called the 'clear retainer ring' were identified internally by Medtronic as early as 2016, and between 2016 and 2019 Medtronic received approximately 74,000 complaints. The FDA ultimately classified Medtronic's response to these defects as a Class I recall — the most serious category, indicating a reasonable probability of serious harm or death. In June and July 2021, the FDA inspected Medtronic's MiniMed manufacturing facility in Northridge, California, and issued a Form 483, a document listing significant objectionable conditions found during an inspection. On December 9, 2021, the FDA issued a Warning Letter citing Medtronic's inadequate risk assessment, complaint handling, and failure to timely report safety issues.

Separately, Medtronic was seeking FDA approval of a new advanced insulin pump model, the MiniMed 780G, which was submitted for FDA review on February 22, 2021. Phoenix alleged that Medtronic executives made misleading public statements between August and December 2021 that overstated the 780G's approval prospects while concealing the impact of the ongoing FDA investigation.

Procedural History

Legal Standards

Phoenix's claims arose under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 (PSLRA). Section 10(b) and its implementing regulation, Rule 10b-5, prohibit fraudulent schemes and material misstatements or omissions in connection with the purchase or sale of securities.

Securities fraud claims are subject to a heightened pleading standard under the PSLRA, requiring plaintiffs to specify each allegedly misleading statement, explain why it is misleading, and state with particularity all facts supporting that belief. Scheme liability claims, while not subject to the PSLRA's heightened standard, must still satisfy the heightened pleading requirements of Federal Rule of Civil Procedure 9(b), which requires pleading 'what manipulative acts were performed, which defendants performed them, when the manipulative acts were performed and what effect the scheme had on the securities at issue.' Scienter — the intent element — must also be pleaded with particularity, requiring facts giving rise to a 'strong inference' of fraudulent intent or severe recklessness.

Section 20(a) 'controlling person' liability is entirely derivative of underlying Section 10(b) violations; if the underlying claims fail, the controlling person claims fail as well.

Misrepresentation Claims

Phoenix grouped its eight alleged misstatements into three categories.

Statements About the 780G Approval Process

Phoenix challenged four statements by Salmon and Martha made between August and November 2021, in which they described their FDA dialogues as 'good' or 'interactive,' said the 780G was 'on track as far as we can tell,' that Medtronic was 'in active dialogue' with the FDA, and was 'making excellent progress.'

Two of these statements (Salmon's August 24, 2021 statement and his November 23, 2021 statement) had already been found inactionable by Judge Menendez as 'inherently subjective statements of optimism, not objective statements of fact.' Judge Provinzino agreed and extended that analysis to the new statements.

As to characterizations of the FDA dialogue as 'good' or 'positive,' the court found these were opinions that Phoenix failed to show were false. The Form 483 addressed manufacturing facility deficiencies unrelated to the 780G approval track, and Phoenix's own counsel acknowledged at oral argument that they did not know whether the 780G approval process had actually stalled between July and December 2021, and that there was 'no allegation that the FDA told the defendants everything is paused.' The court distinguished the case from West Virginia Pipe Trades Health & Welfare Fund v. Medtronic, Inc., 57 F. Supp. 3d 950 (D. Minn. 2014), where the FDA had directly informed Medtronic that a specific product would not be approved — no equivalent direct FDA communication about the 780G was alleged here.

As to statements that the 780G was 'on track' or that Medtronic was 'making good progress,' the court held these were inactionable puffery — vague, optimistic statements devoid of substantive verifiable content that no reasonable investor would rely upon. The court also noted that each allegedly misleading excerpt was paired with cautionary statements acknowledging FDA delays due to COVID and uncertainty about timing, making the overall statements 'hopeful statements, tinged with caution' that cannot reasonably constitute misleading statements.

The court further found no adequate allegation that Medtronic ever assured investors of a specific approval timeline. Analysts' optimistic projections of pre-April 2022 approval could not be attributed to Medtronic.

Statements About FDA Compliance

Phoenix challenged two statements from Medtronic's October 12, 2021 Integrated Performance Report (IPR): (1) that Medtronic 'adhere[s] to regulatory requirements, such as those set by the U.S. FDA,' and (2) that in fiscal year 2021 Medtronic received '0.02 findings per U.S. Food and Drug Administration (FDA) inspection — continuing to demonstrate year-on-year improvements.'

The court applied the framework from Public Pension Fund Group v. KV Pharmaceutical Co., 679 F.3d 972 (8th Cir. 2012), which held that while a company generally has no duty to disclose a Form 483, it may be required to do so when it has also represented compliance with FDA regulations and the Form 483 reflects 'numerous, severe, and pervasive' objectionable conditions. The court found KV Pharmaceutical distinguishable on three grounds: (1) the IPR was a 121-page company-wide document, not formal SEC filings like the five consecutive Form 10-Ks at issue in KV Pharmaceutical; (2) Medtronic's IPR statement was a general principle about how Medtronic manages its business, not a specific unequivocal representation of 'material compliance' with FDA regulations; and (3) the Form 483 involved only one plant making products for one of Medtronic's four business groups, unlike the company-wide violations in KV Pharmaceutical. The court also noted that the fiscal year 2021 data reported in the October 2021 IPR covered a period ending April 30, 2021 — before the FDA's inspection even began — so the statement was not false when made.

Risk Factor Statements in SEC Filings

Phoenix challenged language in Medtronic's September and December 2021 Form 10-Q filings (quarterly financial reports filed with the Securities and Exchange Commission) that described the hypothetical risk that the FDA 'could' take adverse regulatory actions, including denying product approvals, if Medtronic were found non-compliant. Judge Menendez had held these were inactionable forward-looking statements because they 'explicitly identifie[d] the salient risk' without Medtronic knowing the risk had already materialized. Judge Provinzino agreed, finding that the FACC still did not adequately allege that Medtronic knew, at the time of these filings, that the Form 483 had already caused the risks described to materialize.

Scheme Liability Claims

Phoenix's scheme liability claim alleged four categories of deceptive conduct between 2016 and 2021: (1) publication of studies touting the MiniMed pumps' safety while concealing known defects; (2) use of intentionally flawed internal risk analyses that understated the danger from the retainer ring defect; (3) failure to report cybersecurity vulnerabilities to the FDA; and (4) addressing product safety issues through inadequate 'half-measures' rather than comprehensive action.

The court dismissed this claim because Phoenix failed to satisfy Rule 9(b)'s requirement of pleading with particularity which specific defendants performed which specific deceptive acts. The complaint repeatedly attributed conduct to 'the Diabetes Group' or 'the Scheme Defendants' collectively, without connecting specific acts to Hakami or Salmon individually. The court rejected Phoenix's argument that it sufficiently alleged involvement by showing Hakami and Salmon were hands-on leaders of the Diabetes Group during the relevant period, noting that 'corporate management's general awareness of the day-to-day workings of the company's business does not establish scienter.' The court distinguished cases where scheme liability was adequately pleaded — such as In re Galena Biopharma, Inc. Securities Litigation, 117 F. Supp. 3d 1145 (D. Or. 2015), and In re Able Laboratories Securities Litigation, 2008 WL 1967509 (D.N.J. Mar. 24, 2008) — because those cases contained detailed, defendant-specific allegations of particular fraudulent acts, which Phoenix's complaint lacked.

Controlling Person Claims

Because the Section 10(b) misrepresentation and scheme claims both failed, the court dismissed the derivative Section 20(a) controlling person claims against the individual defendants without separate analysis.

Disposition

The court granted Medtronic's motion to dismiss and dismissed the FACC with prejudice. The court based the prejudice determination on the fact that this was Phoenix's second attempt at pleading these claims, and the amended complaint still suffered from the same deficiencies identified in the first dismissal.